Characterization of product-related low molecular weight impurities in therapeutic monoclonal antibodies using hydrophilic interaction chromatography coupled with mass spectrometry-Reference-Cited by-同舟云学术

Characterization of product-related low molecular weight impurities in therapeutic monoclonal antibodies using hydrophilic interaction chromatography coupled with mass spectrometry

Published:2018-05 Issue: Volume:154 Page:468-475
ISSN:0731-7085
Container-title:Journal of Pharmaceutical and Biomedical Analysis
language:en
Short-container-title:Journal of Pharmaceutical and Biomedical Analysis

Author:

Wang Shunhai,Liu Anita P.,Yan Yuetian,Daly Thomas J.,Li Ning

Funder

Regeneron Pharmaceuticals Inc

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry

Reference21 articles.

1. Biopharmaceutical benchmarks 2014;Walsh;Nat. Biotechnol.,2014

2. Billion dollar babies–biotech drugs as blockbusters;Lawrence;Nat. Biotechnol.,2007

3. Effects of protein aggregates: an immunologic perspective;Rosenberg;AAPS J.,2006

4. Immunogenicity of therapeutic protein aggregates;Moussa;J. Pharm. Sci.,2016

5. Fragmentation of monoclonal antibodies;Vlasak;MAbs,2011

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapid identification of antibody impurities in size-based electrophoresis via CZE-MS generated spectral library;Scientific Reports;2024-08-30

2. How spray drying processing and solution composition can affect the mAbs stability in reconstituted solutions for subcutaneous injections. Part II: Exploring each protein stabilizer effect;International Journal of Pharmaceutics;2024-04

3. Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows;mAbs;2024-02-21

4. Characterization of mAb size heterogeneity originating from a cysteine to tyrosine substitution using denaturing and native LC-MS;Journal of Pharmaceutical and Biomedical Analysis;2023-11

5. Comparison of middle- and bottom-up mass spectrometry in forced degradation studies of bevacizumab and infliximab;Journal of Pharmaceutical and Biomedical Analysis;2023-10